Related Experiment Videos
Opiate antagonism fails to reverse post-ECT cognitive deficits.
The Journal of Clinical Psychiatry
|November 1, 1986
Summary
Naloxone, an opiate antagonist, did not improve memory deficits caused by electroconvulsive therapy (ECT) in patients. This study found no significant difference between naloxone and placebo in reversing ECT-induced cognitive impairment.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Opiate antagonist naloxone shows potential in improving memory in animal models and Alzheimer's dementia.
- Electroconvulsive therapy (ECT) can induce temporary cognitive impairment, particularly memory deficits.
Purpose of the Study:
- To investigate the efficacy of naloxone in reversing cognitive impairment, specifically memory deficits, induced by bilateral electroconvulsive therapy (ECT).
Main Methods:
- A double-blind, placebo-controlled study was conducted with 10 patients undergoing bilateral ECT.
- Cognitive performance was assessed using several tests after administration of naloxone or placebo.
Main Results:
- No statistically significant differences in cognitive performance were observed between the naloxone and placebo groups.
- Naloxone did not demonstrate effectiveness in reversing ECT-induced memory deficits at the tested dosages.
Conclusions:
- Naloxone, at the doses administered, is not effective in mitigating or reversing the memory impairments associated with electroconvulsive therapy (ECT).
- Further research may be needed to explore different dosages or alternative therapeutic strategies for ECT-induced cognitive side effects.